Literature DB >> 21312293

The role of nicotine content information in smokers' subjective responses to nicotine and placebo inhalers.

Christine Darredeau1, Sean P Barrett.   

Abstract

OBJECTIVE: A growing body of evidence suggests that non-pharmacological factors may play an important role in smoking cessation outcomes using nicotine replacement therapies. This study examined the role of information about nicotine content in smokers' subjective responses to nicotine and placebo inhalers, using the four conditions of the balanced-placebo design in a mixed within/between-subjects design.
METHODS: Twenty-four adult smokers (12 male) completed two laboratory sessions following overnight abstinence from smoking. Participants were randomly assigned to receive either nicotine inhalers or placebo inhalers in both sessions but were told that they received a nicotine-containing inhaler in one session and a nicotine-free inhaler in the other. In each session participants completed subjective assessments before and after inhaler administration using visual analogue scales and the Brief Questionnaire of Smoking Urges.
RESULTS: While neither nicotine content nor information about it significantly affected cigarette craving associated with withdrawal relief, participants reported a greater reduction in craving associated with intention to smoke when told the inhalers contained nicotine than when told the inhalers were nicotine-free, regardless of actual nicotine content.
CONCLUSIONS: Findings suggest that psychological factors play an important role in smokers' subjective responses to nicotine inhalers, the effects of which cannot be solely attributed to the direct pharmacological effects of nicotine.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21312293     DOI: 10.1002/hup.1159

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

1.  Craving to smoke does not signify physical addiction: a comment on DiFranza et al. (2012).

Authors:  Reuven Dar; Hanan Frenk
Journal:  Psychopharmacology (Berl)       Date:  2012-02-16       Impact factor: 4.530

2.  Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting.

Authors:  Ziyad Ben Taleb; Kenneth D Ward; Taghrid Asfar; Rana Jaber; Rehab Auf; Wasim Maziak
Journal:  Int J Public Health       Date:  2016-04-15       Impact factor: 3.380

3.  Predictors of adherence to pharmacological and behavioral treatment in a cessation trial among smokers in Aleppo, Syria.

Authors:  Ziyad Ben Taleb; Kenneth D Ward; Taghrid Asfar; Raed Bahelah; Wasim Maziak
Journal:  Drug Alcohol Depend       Date:  2015-06-06       Impact factor: 4.492

4.  Varenicline effects on craving, cue reactivity, and smoking reward.

Authors:  Thomas H Brandon; David J Drobes; Marina Unrod; Bryan W Heckman; Jason A Oliver; Richard C Roetzheim; Sloan Beth Karver; Brent J Small
Journal:  Psychopharmacology (Berl)       Date:  2011-05-11       Impact factor: 4.530

5.  Low Nicotine Content Descriptors Reduce Perceived Health Risks and Positive Cigarette Ratings in Participants Using Very Low Nicotine Content Cigarettes.

Authors:  Rachel L Denlinger-Apte; Danielle L Joel; Andrew A Strasser; Eric C Donny
Journal:  Nicotine Tob Res       Date:  2017-10-01       Impact factor: 4.244

6.  Hypnotic Discontinuation Using a Blinded (Masked) Tapering Approach: A Case Series.

Authors:  Constance H Fung; Jennifer L Martin; Cathy Alessi; Joseph M Dzierzewski; Ian A Cook; Alison Moore; Austin Grinberg; Michelle Zeidler; Lara Kierlin
Journal:  Front Psychiatry       Date:  2019-10-24       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.